Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Erasca, Inc. - Common Stock (NQ:ERAS)

8.310 +0.800 (+10.65%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Erasca, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Erasca Insider Sells $671K as Stock Jumps 189% This Past Year ↗
This oncology biotech developing targeted cancer therapies saw a key insider significantly trim their direct equity stake. 
Via The Motley Fool
Topics Regulatory Compliance
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
Via Chartmill
News headline image
The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader
The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood... 
Via MarketMinute
Topics Intellectual Property
News headline image
ERAS Stock Earnings: Erasca Misses EPS for Q2 2024 ↗
ERAS stock results show that Erasca missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
ERAS Stock Earnings: Erasca Misses EPS for Q1 2024 ↗
ERAS stock results show that Erasca missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
ERAS Stock Earnings: Erasca Beats EPS for Q4 2023 ↗
ERAS stock results show that Erasca beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
From FN Media Group LLC
Via GlobeNewswire
News headline image
Fidus Investment, Rocket Companies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
This Accenture Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗
 
Via Benzinga
News headline image
Erasca Narrows Loss 46% in Fiscal Q2 ↗
Via The Motley Fool
News headline image
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
This Spotify Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Stellantis, PG&E And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
e.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying ↗
 
Via Benzinga
News headline image
DXC Technology Issues Weak Outlook, Joins Take-Two Interactive And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Erasca Reports First Quarter 2024 Business Updates and Financial Results
From Erasca, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Erasca Announces $45 Million Oversubscribed Private Placement Financing
Funding from new and existing investors extends anticipated cash runway into H2 2026 
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Erasca, Inc.
Via GlobeNewswire
News headline image
3 Penny Stocks You’ll Regret Not Buying Soon: December Edition ↗
Consider the pros and cons of buying these penny stocks, which can deliver risk-adjusted returns to investors' portfolios. 
Via InvestorPlace
News headline image
RiskOn International And 3 Other Stocks Under $2 Insiders Are Buying ↗
The Dow Jones closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
News headline image
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
From Erasca, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.